
Precision Medicine in Oncology®
Latest News
Advertisement
Latest Videos

CME Content
Advertisement
More News








Amid an explosion of innovation and discovery in the oncology field, researchers are finding it increasingly difficult to recruit enough patients for clinical trials.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of osimertinib as a first-line treatment for patients with non–small cell lung cancer (NSCLC) whose tumors harbor activating EGFR mutations.
















Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
5





































